BeOne Medicines Ltd. (ONC)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 600M 1.2B 1.8B Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 220.2M Q4 '17: 18.2M Q1 '18: 32.5M Q2 '18: 52.8M Q3 '18: 54.2M Q4 '18: 58.7M Q1 '19: 77.8M Q2 '19: 243.3M Q3 '19: 50.1M Q4 '19: 56.9M Q1 '20: 52.1M Q2 '20: 65.6M Q3 '20: 91.1M Q4 '20: 100.1M Q1 '21: 605.9M Q2 '21: 150M Q3 '21: 206.4M Q4 '21: 214M Q1 '22: 306.6M Q2 '22: 341.6M Q3 '22: 387.6M Q4 '22: 380.1M Q1 '23: 447.8M Q2 '23: 595.3M Q3 '23: 781.3M Q4 '23: 634.4M Q1 '24: 751.7M Q2 '24: 929.2M Q3 '24: 1B Q4 '24: 1.1B Q1 '25: 1.1B Q2 '25: 1.3B Q3 '25: 1.4B Q4 '25: 1.5B Q1 '26: 1.5B Q2 '26: 1.7B Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

0 600M 1.2B 1.8B Q1 '23: 366M Q2 '23: 499.3M Q3 '23: 685M Q4 '23: 528.6M Q1 '24: 626.7M Q2 '24: 791M Q3 '24: 831.1M Q4 '24: 967.3M Q1 '25: 952.3M Q2 '25: 1.2B Q3 '25: 1.2B Q4 '25: 1.4B Q1 '26: 1.3B Q2 '26: 1.5B Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Income Quarterly

-600M -400M -200M 0 200M 400M 600M Q3 '16: -34.8M Q4 '16: -37.3M Q1 '17: -51.5M Q2 '17: -58M Q3 '17: 114.9M Q4 '17: -103.8M Q1 '18: -110.8M Q2 '18: -163.1M Q3 '18: -151.1M Q4 '18: -280.8M Q1 '19: -173.8M Q2 '19: -85.8M Q3 '19: -312.3M Q4 '19: -388M Q1 '20: -373.8M Q2 '20: -358.9M Q3 '20: -440.1M Q4 '20: -484.9M Q1 '21: 70.2M Q2 '21: -474.8M Q3 '21: -462.3M Q4 '21: -571.7M Q1 '22: -443.3M Q2 '22: -439.4M Q3 '22: -438.4M Q4 '22: -468.6M Q1 '23: -371.3M Q2 '23: -318.7M Q3 '23: -134M Q4 '23: -383.8M Q1 '24: -261.3M Q2 '24: -107.2M Q3 '24: -120.3M Q4 '24: -79.4M Q1 '25: 11.1M Q2 '25: 87.9M Q3 '25: 163.1M Q4 '25: 185M Q1 '26: 249.9M Q2 '26: 325M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-750M -500M -250M 0 250M 500M 750M Q3 '16: -35.5M Q4 '16: -37.6M Q1 '17: -50.6M Q2 '17: -60.5M Q3 '17: 117.4M Q4 '17: -99.3M Q1 '18: -104.6M Q2 '18: -156.9M Q3 '18: -144M Q4 '18: -268.3M Q1 '19: -167.6M Q2 '19: -85.6M Q3 '19: -307.4M Q4 '19: -388.1M Q1 '20: -363.7M Q2 '20: -335.2M Q3 '20: -425.2M Q4 '20: -472.7M Q1 '21: 66.5M Q2 '21: -480.3M Q3 '21: -438.1M Q4 '21: -590.7M Q1 '22: -435.2M Q2 '22: -565.7M Q3 '22: -557.6M Q4 '22: -445.3M Q1 '23: -348.4M Q2 '23: -381.1M Q3 '23: 215.4M Q4 '23: -367.6M Q1 '24: -251.2M Q2 '24: -120.4M Q3 '24: -121.3M Q4 '24: -151.9M Q1 '25: 1.3M Q2 '25: 94.3M Q3 '25: 124.8M Q4 '25: 66.5M Q1 '26: 227.4M Q2 '26: 237M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

0 35M 70M 105M Q3 '17: 1.9M Q4 '17: 3M Q1 '18: 4.5M Q2 '18: 6.3M Q3 '18: 8.7M Q4 '18: 9.2M Q1 '19: 15.3M Q2 '19: 17.8M Q3 '19: 20.1M Q4 '19: 18M Q1 '20: 14.1M Q2 '20: 14.3M Q3 '20: 21.1M Q4 '20: 21.1M Q1 '21: 32.7M Q2 '21: 36.3M Q3 '21: 47.4M Q4 '21: 48.5M Q1 '22: 65.2M Q2 '22: 71.2M Q3 '22: 76.5M Q4 '22: 73.5M Q1 '23: 81.8M Q2 '23: 96M Q3 '23: 96.3M Q3 '17 Q3 '18 Q3 '19 Q3 '20 Q3 '21 Q3 '22 Q3 '23

Operating Cash Flow Quarterly

-600M -400M -200M 0 200M 400M 600M Q3 '16: -24.3M Q4 '16: -26.1M Q1 '17: -35.7M Q2 '17: -51.9M Q3 '17: 6.6M Q4 '17: 93.7M Q1 '18: -104.5M Q2 '18: -117.1M Q3 '18: -132.2M Q4 '18: -193.9M Q1 '19: -172M Q2 '19: -46.1M Q3 '19: -265M Q4 '19: -267.2M Q1 '20: -341.9M Q2 '20: -262.9M Q3 '20: -346.2M Q4 '20: -332.3M Q1 '21: 125.1M Q2 '21: -420.3M Q3 '21: -495.7M Q4 '21: -507.8M Q1 '22: -236.6M Q2 '22: -380M Q3 '22: -561.9M Q4 '22: -318.2M Q1 '23: -563.8M Q2 '23: -293.9M Q3 '23: -78.2M Q4 '23: -221.6M Q1 '24: -308.6M Q2 '24: -95.6M Q3 '24: 188.4M Q4 '24: 75.2M Q1 '25: 44.1M Q2 '25: 263.6M Q3 '25: 402.6M Q4 '25: 417.3M Q1 '26: 201.3M Q2 '26: 462.8M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-750M -500M -250M 0 250M 500M 750M Q3 '16: -31M Q4 '16: -34.2M Q1 '17: -40.8M Q2 '17: -55.7M Q3 '17: -12M Q4 '17: 74.8M Q1 '18: -114.2M Q2 '18: -127.8M Q3 '18: -158.9M Q4 '18: -217.1M Q1 '19: -193.8M Q2 '19: -67.5M Q3 '19: -295.9M Q4 '19: -282.6M Q1 '20: -363.5M Q2 '20: -295.5M Q3 '20: -374.9M Q4 '20: -367M Q1 '21: 82.7M Q2 '21: -458.8M Q3 '21: -562.8M Q4 '21: -622.8M Q1 '22: -281.7M Q2 '22: -430.2M Q3 '22: -670.6M Q4 '22: -439.5M Q1 '23: -689.4M Q2 '23: -415.4M Q3 '23: -236M Q4 '23: -378.6M Q1 '24: -465.1M Q2 '24: -205.5M Q3 '24: 54.7M Q4 '24: -17.3M Q1 '25: -12.3M Q2 '25: 219.8M Q3 '25: 354.5M Q4 '25: 379.8M Q1 '26: 160.5M Q2 '26: 435.3M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 600M 1.2B 1.8B Q3 '16: 428.1M Q3 '17: 600.6M Q3 '18: 739.8M Q1 '20: 1B Q2 '20: 1B Q3 '20: 1.1B Q1 '21: 1.3B Q2 '21: 1.2B Q3 '21: 1.2B Q1 '22: 1.3B Q2 '22: 1.3B Q3 '22: 1.3B Q1 '23: 1.4B Q2 '23: 1.4B Q3 '23: 1.4B Q1 '24: 1.4B Q2 '24: 1.4B Q3 '24: 1.4B Q1 '25: 1.4B Q2 '25: 1.5B Q3 '25: 1.5B Q1 '26: 1.5B Q2 '26: 1.5B Q3 '17 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.80 -1.20 -0.60 0.00 0.60 1.20 1.80 Q3 '16: -0.44 Q4 '16: -0.29 Q1 '17: -0.32 Q2 '17: -0.38 Q3 '17: -0.10 Q4 '17: -0.19 Q1 '18: -0.25 Q2 '18: -0.35 Q3 '18: -0.74 Q4 '18: -0.92 Q1 '19: -0.98 Q2 '19: -0.87 Q3 '19: -1.07 Q4 '19: -1.21 Q1 '20: -1.35 Q2 '20: -1.57 Q3 '20: -1.55 Q4 '20: -1.46 Q1 '21: -1.05 Q2 '21: -1.12 Q3 '21: -1.11 Q4 '21: -1.20 Q1 '22: -1.58 Q2 '22: -1.60 Q3 '22: -1.65 Q4 '22: -1.49 Q1 '23: -1.42 Q2 '23: -1.28 Q3 '23: -0.72 Q4 '23: -0.66 Q1 '24: -0.59 Q2 '24: -0.40 Q3 '24: -0.64 Q4 '24: -0.48 Q1 '25: -0.29 Q2 '25: -0.14 Q3 '25: 0.03 Q4 '25: 0.18 Q1 '26: 0.33 Q2 '26: 0.43 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.